|
Accueil > Actualité
GSK: China approves Cervarix HPV vaccine
(CercleFinance.com) - GSK announced on Friday that China has approved the marketing of its Cervarix vaccine against the human papillomavirus (HPV) in girls aged 9 to 14.
The British pharmaceutical company said the green light from the China National Medicines Regulatory Agency (NMPA) was for a two-dose regimen. Cervarix is indicated for the prevention of cervical cancer, cervical intraepithelial neoplasia and adenocarcinoma caused by virus types 16 and 18. GSK says that in 2020, some 110,000 new cases of cervical cancer were reported in China, resulting in nearly 59,000 deaths. The company has also announced that it will present 25 abstracts at the American Society of Clinical Oncology (ASCO) annual meeting next week. Copyright (c) 2022 CercleFinance.com. All rights reserved. |
19/04/2024 11:55
Airbusnouveaux hélicoptères pour l'armée britannique 19/04/2024 11:10 Renaultle titre chute après l'avertissement de Nissan 19/04/2024 11:07 Arganune nomination au directoire 19/04/2024 10:50 Econocomconfirme une hausse du CA comprise entre 3 et 5% 19/04/2024 10:42 Umicoreles obligations durables placées avec succès 19/04/2024 10:30 Keyruscroissance de 5,2% du chiffre d'affaires Tous les articles sociétés |
